Abstract Background and objectives: Patients with beta thalassemia major are at higher risk of acquiring reticulocytopenia, and cessation of erythropoiesis after exposure to parvovirus B19. The aim of the study was to detect the seroprevalence of parvovirus B19 infection in children with transfusion dependent beta-thalassemia major through the detection of its specific IgM and IgG in their sera by Enzyme-linked Immunosorbent Assay (ELISA) in the Pediatric Department of Fayoum University Hospital. Materials and methods: A cross sectional descriptive study was carried out from July to September 2013, in the Pediatric Department of Fayoum University Hospital in Egypt. A total of fifty-five children with beta-thalassemia major aged from 2 to 16 years were enrolled in the study. All patients were subjected to history taking, examination and investigations including; Complete blood count, serum creatinine, blood urea, hepatitis B surface antigen (HBsAg), anti hepatitis C virus antibody (anti HCV), reticulocytic count, anti B19 IgM and IgG. Results: Anti-B19 IgM antibodies (recent infection) were detected in 14.5% (8 patients), while anti B19 IgG antibodies (prior infection) were detected in 18.2% (10 patients) of transfusion dependent thalassemic patients. There was a significant statistical correlation between the history of other siblings with beta thalassemia major, the hepatitis C virus and hepatitis B virus infection regarding absent, prior and recent infection. Conclusion: Parvovirus B19 infection is detected in high rates among children with beta thalassemia major. Measures to avoid iatrogenic and nosocomial transmission have to be implemented including screening of donated blood for B19 especially blood given to patients with hematological disorders. Also data from this study support the need for introduction of an approved B19 vaccine that primarily protects children with thalassemia major against that infection.
Introduction
In Egypt, it was estimated that 1.000/1.5 million per year live births will suffer from thalassemia. 1 Patients with beta thalassemia major, are at higher risk of acquiring aplastic crisis, sudden worsening of anemia, reticulocytopenia, and cessation of erythropiosis of the bone morrow after exposure to parvovirus B19. 2 Also B19 infection results in a severe drop of hemoglobin values and anemia which could be lifethreatening. 3 Transmission of B19 occurs via respiratory droplets, contaminated blood, organ transplantation and vertical transmission from mother to fetus. 4 The aim of this study was to detect the seroprevalence of parvovirus B19 infection in multitransfused beta-thalassemia major patients at Pediatric Department of Fayoum University Hospital.
Materials and methods
A cross sectional descriptive study was carried out from July to September 2013, in the Pediatric Department of Fayoum University Hospital in Egypt. A total of 55 children (26 female and 29 male) aged from 2 to 16 years with mean age 6.2 ± 13.25 years were enrolled in the study; all of them have transfusion dependent beta thalassemia major and are receiving medical care at Pediatric Department of Fayoum University Hospital. All patients were under a hypertransfusion regimen and treated with regular transfusion of packed red blood cells. Exclusion criteria were patients with other hemoglobinopathies such as sickle cell anemia and anemia due to other causes.
All the included subjects were treated according to the Helsinki Declaration of biomedical ethics, 5 informed consent was obtained from the parents, and the Ethics Committee of the Medical Faculty of Fayoum University approved the study protocol.
Data collection was carried out using a field pre-tested interviewing questionnaire covering the following elements:
History of thalassemia; complications and frequency of blood transfusion along the course of the disease. History of B19 infections manifestations; characteristic ''slapped cheeks" rash, joint manifestations, previous or recent episodes of transient aplastic crisis ''TAC" (severe pallor, tachycardia, tachypnea ±a rash). History of vaccination especially to hepatitis B virus.
A fully detailed clinical examination for identifying recent B19 infections and the manifestations of the chronic hematologic conditions was done, documented in the form of checklists for B19 fulfilling all useful items of personal data, history and clinical examination.Collection of all lab data from patients' files e.g. CBC, kidney function (urea and creatinine), liver functions (ALT and AST) and hepatitis B and C virus status.
Sample collection and preparation
Ten milliliters of blood was drawn from the antecubital fossa of each subject after obtaining informed consent. The 10 ml of blood was divided into two aliquots, 3 ml was added into EDTA anticoagulated bottle and was used for basic complete blood count (CBC), while the remaining 7 ml was added into a plain specimen container allowed to clot. After clotting, blood samples in the plain tubes were centrifuged at 3000 rpm for 10 min and the resulting sera were collected into separate cryo tubes for biochemistry and serological analysis of B19 IgM and IgG antibodies. The serum samples were used immediately or stored at À20°C until tested. 
Determination of

Results
A total of 55 children were enrolled in the study: 22 patients (40%) aged <5 years, 26 patients (47.2%) aged 5-10 years and 7 patients (12.8%) aged >10 years. According to the results of parvovirus B19 IgG and IgM antibodies by ELISA, it was found that 37 patients (67.3%) had no infection (both IgM & IgG were negative), 10 patients (18.2%) had prior infection (IgG +ve & IgM Àve) and 8 patients (14.5%) had recent infection (IgM +ve & IgG Àve or +ve). As regards the clinical manifestations of parvovirus B19; transient aplastic crises were found in 2 patients (3.6%) also 2 patients (3.6%) had a history of arthralgia and no one had a rash while 96.4% were asymptomatic. History of vaccination against hepatitis B was irrelevant. As regard to number of blood transfusions: Of children who received less than 10 blood transfusion (6 patients), 2 of them had no infection, 2 had prior infection and 2 had recent infection. Of children who received more than 10 blood transfusions (49 patients), 35 of them had no infection, 7 had prior infection and 7 had recent infection. P value between the 2 groups was insignificant (0.162).
History of other siblings with beta thalassemia major was positive with 15 patients; 2 of them had no infection, 8 had prior infection and 5 had recent infection. It was negative with 40 patients; 35 of them had no infection, 2 had prior infection and 3 had recent infection. P value between the 2 groups was significant (0.001).
Age below 5 years (21 patients); 17 of them had no infection, 1 had prior infection and 3 had recent infection. Age from 5 to 10 years (26 patients); 17 of them had no infection, 6 had prior infection and 3 had recent infection. Age more than 10 years (8 patients); 3 of them had no infection, 3 had prior infection and 2 had recent infection. P value between the 3 groups was insignificant; (0.166). Table 1 shows that 10.9% (6 patients) had a history of splenectomy, 38.2% (21 patients) had a history of intercurrent infection, 27.3% (15 patients) had a history of pathological fractures, 9.1% (5 patients) had HCV infection, and 3.6% (2 patients) had HBV infection. There was a significant statistical correlation between the HCV and HBV infection regarding absent, prior and recent infections. Table 2 shows that there was a significant statistical correlation between Hb% and retics with B19 seroprevalence. There were statistically significant difference between thalassemic patients of recent and absent infections and thalassemic patient of recent and prior infections. Table 3 shows that there was no significant statistical correlation between BUN, creatinine and ALT with B19 seroprevalence.
Discussion
Patients with beta thalassemia major are at higher risk of acquiring aplastic crisis, sudden worsening of anemia, reticulocytopenia, and cessation of erythropoiesis of the bone morrow (transient aplastic crisis) after exposure to parvovirus B19 infection. 4 The aim of this study was to detect the prevalence of parvovirus B19 in children with transfusion dependent beta-thalassemia major through the detection of its specific IgM and IgG in their sera by ELISA.
In the present study, the prevalence of B19 specific IgG (prior infection) was 18.2% while the prevalence of B19 specific IgM (recent infection) was 14.5%, comparable to other studies in Tunis (75 cases) it was 0% for IgM and 39.1% for IgG, 6 in Iraq (46 cases) it was 13% for IgM and 30.4% for IgG 7 and in India (90 cases) it was 40.1% for IgM and 81% for IgG. 8 All the variations in B19 seropositivity between different regions of the world, clarify that climate, variable socioeconomic status, overcrowding and geographical distribution may have effective influence on B19 seroprevalence. It may also be attributed to difference in immunological and/or hematological status of participants.
In the present study, prior B19 infection (as diagnosed by presence of IgG only) had a higher rate (18.2%) than recent infection (14.5%). In accordance with another Egyptian study, who reported 40% prevalence of prior B19 infection in various types of chronic hemolytic anemia they reported a lower rate of recent infection (24%). 9 This difference in rate of recent B19 infection may be attributed to different socioeconomic standards, frequency of blood transfusions and possibility of nosocomial exposure.
This work showed no significant association between B19 seroprevalence and the number of blood transfusions. This is in accordance with Iheanacho et al. who found that there is no statistically significant difference between the control group and the sickle cell anemia patients as regards the seroprevalence of B19 infection. 10 This may suggest that blood transfusion may not be the major means of transmission of parvovirus. Contrary to our findings, Lee et al., reported increased seropositive rates of parvovirus infections associated with blood transfusion. The present study showed significant association between prevalence of B19 and history of other siblings in the family with beta-thalassemia major. This is consistent with Alao et al. who reported that B19 is known to be highly infectious. The secondary attack rates between 50% and 60% have been reported. 12 This study evaluated the hematological profile of thalassemic patients with and without IgG seropositivity. There were no significant differences in hemoglobin concentration, total leukocytic count, platelet count and reticulocytic count between IgG seropositive (prior infection) and IgG seronegative (absent infection) thalassemic patients. This may be explained by that the presence of this class of antibody is generally indicative of either the later stages of a current infection, or of a past infection. Thus these findings are in keeping with the well documented observation that; If a patient survives the transient marrow aplasia, recovery is usually complete and no clinical or hematological traces of previous infection are found. 13 In contrast with Girei et al. who found statistically significant difference in the mean absolute platelet count between IgG seropositive and IgG seronegative subjects. 14 Our study revealed that the mean hemoglobin concentration and the mean reticulocyte index are lower among IgM seropositive thalassemic subjects (recent infection) as compared to IgM seronegative (absent infection) and IgG seropositive (prior infection) thalassemic subjects and the differences were statistically significant. Also, we found that the mean absolute platelet count and the mean total leukocytic count were lower among IgM seropositive subjects as compared to IgM seronegative and IgG seropositive subjects but the differences were not statistically significant. The latter results are similar to Zaki et al. and Ensaf et al. who reported anemia and reticulocytopenia as a constant feature in patients with hematologic disorders recently infected with B19. 15, 9 Our study revealed that the mean ALT is higher among IgM seropositive thalassemic subjects (recent infection) as compared to IgM seronegative (absent infection) and IgG seropositive (prior infection) thalassemic subjects but the differences were not statistically significant. In agreement with Bamidele et al. who reported that parvovirus B19 infection caused elevation in liver enzymes in infected sickle cell anemia patients and the differences were statistically significant. 16 The present study showed no significant association between B19 and HCV and HBV infection. Co-existence of B19 infection along with HBV and HCV was seen in two (3.6%) and five (9.1%) thalassemic patients respectively. In agreement with a study done by Kishore et al. who found that co-existence of B19 infection along with HBV and HCV was seen in four (4.4%) and seven (7.7%) thalassemia patients respectively. 8 This is explained by that the thalassemic patients are on a hyper-transfusion regimen, hence, are at higher risk of acquiring transfusion transmitted viruses.
Our study has some limitations, we could not figure out whether transient aplastic crises (TAC) had been significantly presented among our thalassemic patients of prior infection. Not even a single documented diagnosed TAC attack was present in their medical reports. Also, we could not demonstrate its incidence or impact on their health status. This may be explained by the underestimation of B19 BM aplasia (i.e. we always search first for other viral causes as EBV, hepatitis viruses, secondary drug causes or others). Again lack of human parvovirus B19 diagnostic tools in our laboratories is another reason. Moreover the hypertransfusion regimen in managing thalassemic patients may bridge the gap between BM suppression and its recovery concealing TACs. The seroprevalence of B19 in normal Egyptian population is not known. Finally the direct detection of DNA by PCR in sera needs to be coupled to serology for a more reliable diagnosis of B19 infections in those children.
Conclusions
Parvovirus B19 infection is detected in high rates among children with beta thalassemia major (prior infection; 18.2% and recent infection; 14.5%). It should be suspected when a thalassemic child develops a sudden drop in hemoglobin (TAC) and when other siblings with beta thalassemia are seropositive for B19. In Egypt, further researches are needed to detect B19 prevalence among our general pediatric population. Measures to avoid iatrogenic and nosocomial transmission have to be implemented including screening of donated blood for B19 especially blood given to patients with hematological disorders.
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